Michael Pace has carved a record of global health technology commercial growth at the intersection of biotechnology, chemical engineering, software development, and value-based healthcare.

Mike formed and led the trailblazing Market Access, Health Economics, and Real World Evidence team at prescription digital therapeutics (PDT)-, software as a medical device (SaMD)-pioneering Pear Therapeutics from May 2019 until March 2021. Prior to joining Pear, he was SVP Divisional Principal at ICON plc, where he led the firm’s Value Strategy Consulting practice and Pricing Market Access team of 60 consultants in the US and Europe. Mike has held chief commercial, product, and business development roles with digital health companies including OM 1 and Beansprout Networks (acquired by IQVIA), as well as leading sales, marketing, training leadership development and managed markets functions during his tenure with specialty and primary care biopharmaceutical leaders EMD Serono, Allergan, and Sanofi predecessor companies.